Pentoxifylline reduces the first-dose reactions following OKT3.
Vincenti
F G
FG
Kidney Transplant Service, University of California, San Francisco 94143.
Vasconcelos
M
M
Birnbaum
J L
JL
Tomlanovich
S J
SJ
Amend
W J
WJ
Melzer
J S
JS
Snyder
J P
JP
D000082:Acetaminophen / Q000627:therapeutic use; D015703:Antigens, CD / Q000032:analysis; D001706:Biopsy; D017252:CD3 Complex / Q000032:analysis; D004155:Diphenhydramine / Q000627:therapeutic use; D006084:Graft Rejection / Q000473:pathology / Q000628:therapy*; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology; D016853:Muromonab-CD3 / Q000009:adverse effects* / Q000627:therapeutic use; D010431:Pentoxifylline / Q000627:therapeutic use*; D011239:Prednisolone / Q000627:therapeutic use; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D015703:Antigens, CD; D017252:CD3 Complex; D016853:Muromonab-CD3; D014409:Tumor Necrosis Factor-alpha; D000082:Acetaminophen; D004155:Diphenhydramine; D011239:Prednisolone; D010431:Pentoxifylline